Plant Name: Humata pectinata
Taxonomic Information:
Plant ID: NPO15795
Plant Latin Name: Humata pectinata
Taxonomy Genus: Humata
Taxonomy Family: Davalliaceae
Plant External Links:
NCBI TaxonomyDB:
1144422
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| NPSR1; | |
| ACHE; | |
| PIM1; MET; AXL; FLT3; CDK1; KDR; IGF1R; AURKB; | |
| CA2; CA1; CA12; CA14; CA7; CA4; | |
| ALOX12; HSD17B10; NOX4; POLB; | |
| KDM4E; | |
| MMP9; MMP1; MMP12; MMP2; | |
| HIF1A; NFKB1; | |
| FUT7; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.061E-14 | 1.102E-09 | CA1, CA12, CA14, CA2, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.912E-11 | 5.017E-07 | CA1, CA12, CA14, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.762E-09 | 8.592E-06 | CA1, CA12, CA2, CA4, CA7 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 2.412E-07 | 2.388E-04 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 6.864E-07 | 5.154E-04 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 7.287E-07 | 5.289E-04 | ALOX12, CDK1, FLT3, HIF1A, IGF1R, KDR, MMP12, MMP2, MMP9, PIM1 |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 3.431E-06 | 1.756E-03 | MMP1, MMP12, MMP2, MMP9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.467E-06 | 1.756E-03 | CA1, CA12, CA2, CA4, CA7, MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 7.471E-06 | 2.864E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 7.497E-06 | 2.864E-03 | MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 1.088E-05 | 3.644E-03 | AXL, FLT3, IGF1R, KDR, MET |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 1.401E-05 | 4.124E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0008152; metabolic process | GO:0072593; reactive oxygen species metabolic process | 2.066E-05 | 5.555E-03 | ALOX12, CYP1A1, CYP1B1, NOX4 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 3.088E-05 | 7.911E-03 | AURKB, CDK1, CYP1A1, NOX4, POLB |
| MF | GO:0003824; catalytic activity | GO:0004222; metalloendopeptidase activity | 3.313E-05 | 8.198E-03 | MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 3.428E-05 | 8.386E-03 | AXL, FLT3, HIF1A, POLB |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 3.724E-05 | 8.911E-03 | CA1, CA2 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.014E-13 | 1.146E-11 | CA12, CA1, CA2, CA4, CA7, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.188E-07 | 6.714E-06 | FLT3, MMP1, MMP2, HIF1A, MET, MMP9, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 6.051E-07 | 2.279E-05 | MMP2, KDR, HIF1A, MMP9, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 7.849E-06 | 2.217E-04 | FLT3, MMP9, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 3.454E-05 | 7.805E-04 | MMP1, MMP2, MMP9 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 6.290E-05 | 1.185E-03 | CYP1A1, CYP1B1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 8.643E-05 | 1.317E-03 | PIM1, CYP1B1, MMP9, MET, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 9.322E-05 | 1.317E-03 | FLT3, PIM1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.510E-04 | 1.896E-03 | FLT3, MET, HIF1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 3.997E-04 | 4.517E-03 | KDR, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 5.070E-04 | 5.011E-03 | MMP2, PIM1, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 5.369E-04 | 5.011E-03 | HIF1A, NFKB1, IGF1R |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 5.764E-04 | 5.011E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
| NA: NA | Edema | NA | CA2; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| NA: NA | GIST | NA | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; CA1; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; HIF1A; MMP9; MMP2; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; ACHE; HIF1A; MMP9; MMP2; CA1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
